Latest research on dexlansoprazole

TAK-390MR is an investigational for the treatment of acid related disorders.. TAK-390MR employs a new modified release (MR) technology on an enantiomer of lansoprazole.

dexlansoprazole interactions

CYP2C19 inhibitors included Omeprazole and esOmeprazole, and CYP2C19 non-inhibitors included dexlansoprazole, lansoprazole, Pantoprazole, and Rabeprazole [18,19]. [source, 2016]
Pantoprazole and dexlansoprazole were the only PPIs with a significant increased use post-safety communication (3.9% vs. 6.1% and 0.0% vs. 0.5%, respectively) ( [source, 2016]
Patients transferring from CYP2C19 inhibitors mainly took the non-inhibitor PPIs Pantoprazole and dexlansoprazole. [source, 2016]
In the current study, the main decreases were observed for esomeprazole, followed by lansoprazole; which were partially replaced by Pantoprazole and dexlansoprazole. [source, 2016]
Pantoprazole and dexlansoprazole are the only two PPIs that had an increase in their prescription trends during the post-safety communication period. [source, 2016]
In October 2011 the Pantoprazole and dexlansoprazole drug labels were changed to indicate no important clinical impact on Clopidogrel metabolism [21,22]. [source, 2016]
In addition, studies published in 2010 [23] and 2011 [24] for Pantoprazole and in 2012 for dexlansoprazole [25] showed reduced metabolic drug-drug interaction with Clopidogrel, compared to Omeprazole. [source, 2016]
PPIs with brand name only formulations available for the entire study period (2006–2010) included esomeprazole (Nexium), Rabeprazole (Aciphex), omeprazole/sodium bicarbonate (Zegerid), and dexlansoprazole (Dexilant). [source, 2015]
In general, the differences between available PPIs (esomeprazole, dexlansoprazole, lansoprazole, omeprazole, Pantoprazole, Rabeprazole) are small. [source, 2015]
A recent randomized, open-label, two-period crossover study examined the effects of four different PPIs (including dexlansoprazole MR, lansoprazole, Omeprazole, and esOmeprazole) on the pharmacokinetics and pharmacodynamics of Clopidogrel. [source, 2015]